Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 512 results for "biocon"

150 women government employees screened for cancer
Times of India

150 women government employees screened for cancer

BENGALURU: Over 150 women government employees benefitted from screening camps conducted by Biocon foundation and the state government on January 16 and 17 at Vidhana Soudha. The CSR wing of the pharmaceutical giant took to sensitizing women about ... Times of India, 3 days ago

157 images for biocon

PharmaVOICE, 1 week ago
India Infoline, 1 week ago
Pharma Letter, 1 week ago
Pharmafile, 1 week ago
DNA India, 1 week ago
Pharmaceutical Business Review, 1 week ago
4 Traders, 1 week ago
Bio-Medicine, 1 week ago
Nasdaq, 1 week ago
European Pharmaceutical Review, 1 week ago

BIOCON : U.S. FDA Accepts Biologics License Application BLA for Mylan and Biocon's Proposed Biosimilar Trastuzumab

By a News Reporter-Staff News Editor at Women's Health Weekly -- - Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan's biologics license ...
 4 Traders2 days ago US FDA accepts Mylan's BLA for proposed trastuzumab product  CPhI.cn6 days ago Biocon Bucks Pharma Fall On U.S. Biosimilar Boost  Bloomberg-Quint1 week ago Biocon up 3% as USFDA accepts Trastuzumab license application  DNA1 week ago

In Biocon, investors see a blockbuster pipeline

Biocon had launched drug in India in 2014 and is in process of expanding its presence
 Business Standard4 days ago Strong growth prospects: In Biocon, investors see a blockbuster pipeline  Business Standard4 days ago 'Make in India' strategy to kickstart domestic biomanufacturing, Biocon  BioPharma-Reporter.com1 month ago

Biocon at new high as USFDA accepts application for cancer drug

Biocon shares touched a record high of Rs 1,049.50 on Thursday, up nearly 5 percent intraday after the US health regulator has accepted biosimilar application for its proposed cancer drug.
 Money Control1 week ago Biocon hits new high after USFDA accepts cancer drug biosimilar application  Smart Investor1 week ago LIVE BLOG: Biocon, NTPC among stocks in focus  Economic Times1 week ago Biocon hits new 52-week high  India Infoline1 week ago
Times of India

Biocon Academy trains 110 industry ready graduates looking to pursue careers in biotech sector

Biocon Academy, a Centre of Excellence for Advanced Biosciences Learning, has announced that its 110 students donned their graduation caps to take on aspiring careers in the biotech industry. The convocation ceremony was held for students ...
 PharmaBiz1 week ago 110 students graduate from Biocon Academy  Express Pharma2 weeks ago RSSDI awards Biocon's ABIDE for diabetes education initiative  Times of India1 month ago

Too Late? Biocon And Mylan's $7 Billion Bet

Last week, Biocon ( OTC:BCNQY ) and Mylan (NASDAQ: MYL ) announced successful trials for their biosimilar trastuzumab. The two companies have been working together to jointly develop a biosimilar trastuzumab, which treats metastatic breast cancer.
 Seeking Alpha1 week ago Mylan and Biocon submit trastuzumab biosimilar to FDA  GaBi Online1 month ago Biocon, Mylan submit BLA for MYL-1401O to USFDA  Deccan Herald2 months ago Mylan, Biocon submit application for biosimilar to USFDA  Business Line2 months ago

Biocon sustains Trump tamper; up more than 2%

The Indian Pharma stocks on Jan 12 were hit sharply by US President-elect Donald Trump as he hinted towards coming down hard on the lobbying in the pharma industry.
 India Infoline1 week ago I don't see Trump's views affecting Indian drug cos: Biocon CMD  Money Control1 week ago BIOCON : sustains Trump tamper; up more than 2%  4 Traders1 week ago Top 6 stocks that mutual fund houses picked in November  Economic Times1 month ago

Biocon scales record high as USFDA accepts BLA for proposed biosimilar Trastuzumab

Biocon rose 3.46% to Rs 1,036.50 at 10:35 IST on BSE after the company and its US partner Mylan said the US Food and Drug Administration has accepted the biologics licence application for its biosimilar drug to treat breast cancers.
 Business Standard1 week ago

Stocks To Watch: TCS, Biocon, Idea Cellular And More

Bloomberg | Quint is a multiplatform, Indian business and financial news company. We combine Bloomberg's global leadership in business and financial news and data, with Quintillion Media's deep expertise in the Indian market and digital news ...
 Bloomberg-Quint1 week ago

Biocon drops on profit booking after hitting record high

Biocon fell 1.84% to Rs 994.40 at 14:45 IST on BSE on profit booking after gaining 8.26% in prior three sessions.
 Business Standard1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less